View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
In association with Cytiva for Cell & Gene Therapy coverage
  1. News
December 21, 2021

FDA puts clinical hold on bluebird bio’s sickle cell gene therapy trial

The partial suspension to treat adolescent SCD patients comes after a subject aged under 18 developed persistent anaemia.

The US Food and Drug Administration (FDA) has placed a partial clinical hold on bluebird bio’s clinical programme for lovotibeglogene autotemcel (lovo-cel) gene therapy to treat sickle cell disease (SCD) in adolescents.

An experimental one-time therapy, lovo-cel can potentially provide functional copies of a modified form of the β-globin gene into the blood stem cells of the patients. This approach aids in producing anti-sickling haemoglobin (HbAT87Q) that lowers the HbS proportion.

The move comes after an adolescent trial participant contracted persistent, non-transfusion-dependent anaemia 18 months after receiving lovo-cel.

The participant is in good clinical condition, with no signs of malignancy or clonal predominance, the company said.

With the partial suspension, the company will halt the dosing and administration of the trial drug in subjects aged below 18 years.

Recruitment and dosing of the SCD patients aged 18 years and above living in the HGB-206, HGB-210 and LTF-307 trials and follow up of already treated subjects of all age groups in all trials will progress as scheduled.

In accordance with the clinical hold, bluebird expects to receive written queries from the FDA early next year. The company plans to work rapidly to provide answers that could aid in lifting the partial hold.

It is assessing the potential effect of the partial clinical hold on the filing of biologics license application (BLA) expected in the first quarter of 2023.

bluebird bio chief medical officer Richard Colvin said: “Consistent with the FDA’s direction, we have paused enrolment and treatment of patients younger than 18 in our SCD clinical programme, and we will continue to work collaboratively with the FDA to understand and address their concerns.

“While the partial hold is in place, we intend to continue planned follow-up on previously treated patients from HGB-206 and HGB-210 and plan to enrol and treat new adult patients with lovo-cel through study HGB-210 to further characterise the efficacy and safety of lovo-cel for patients with SCD and to continue to advance the field of gene therapy.”

In June this year, the FDA lifted the clinical hold placed on the company’s gene therapy trials.

Cell & Gene Therapy Coverage on Clinical Trials Arena supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.

Free Whitepaper

Secure the cell therapy supply chain from bench to bedside

The development of cell therapies is changing healthcare, delivering new hope to thousands of patients around the world. The vein-to-vein workflow for these therapies, however, is not without challenges, many of which will increase as we scale up to treat more patients. Download this free guide from Cytiva to learn more about the challenges and risks associated with the cryogenic supply chain for cell therapies, and how supply chain disruptions can best be mitigated.
by Cytiva Thematic

By clicking the Download Free Whitepaper button, you accept the terms and conditions and acknowledge that your data will be used as described in the Cytiva Thematic privacy policy By downloading this Whitepaper, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Clinical Trials Arena